论文部分内容阅读
我院于1964年5月至1978年12月采用~(60)Co治疗食管癌509例,其中病变位于中段者占74.66％,上段18.66％下段6.48％;病变长度大于5cm占69.16％。全组1、3、5年生存率分别为40.80％、16.11％、11.39％;而单纯放疗471例分别为39.07％,15.07％,10.62％;术前放疗21例分别为71.43％,42.86％,33.33％;术后放疗17例分别为29.41％,11.76％,5.88％。影响预后因素为:病变部位居于上段,病变长度≤5cm,定位准确,剂量6000至8000CGY,疗效较优。对中晚期食管癌,采用积极放疗加手术综合治疗,可以提高疗效。对足量(6,000CGy以上)放疗后X线检查病灶未消者加手术治疗,可以挽救部分病人生命。
In our hospital from May 1964 to December 1978, ~(60)Co was used to treat 509 cases of esophageal cancer, of which lesions located in the middle segment accounted for 74.66%, the upper segment 18.66% in the lower segment 6.48%; lesion length greater than 5cm accounted for 69.16%. The overall 1-, 3-, and 5-year survival rates were 40.80%, 16.11%, and 11.39%, respectively; while 471 cases were treated with radiotherapy alone with 39.07%, 15.07%, and 10.62%; 21 cases with preoperative radiotherapy were 71.43% and 42.86%, respectively. 33.33%; 17 cases of postoperative radiotherapy were 29.41%, 11.76%, 5.88%. The factors affecting the prognosis are: the lesion site is in the upper segment, the lesion length is ≤ 5cm, and the positioning is accurate. The dose is 6000 to 8000CGY, and the curative effect is better. For advanced esophageal cancer, active radiotherapy combined with surgical treatment can improve the efficacy. More than enough (more than 6,000 CGy) radiotherapy after X-ray examination of the lesions plus surgery can save some patients’ lives.